131 related articles for article (PubMed ID: 10600919)
1. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans.
Matzinger D; Gutzwiller JP; Drewe J; Orban A; Engel R; D'Amato M; Rovati L; Beglinger C
Am J Physiol; 1999 Dec; 277(6):R1718-24. PubMed ID: 10600919
[TBL] [Abstract][Full Text] [Related]
2. The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans.
Matzinger D; Degen L; Drewe J; Meuli J; Duebendorfer R; Ruckstuhl N; D'Amato M; Rovati L; Beglinger C
Gut; 2000 May; 46(5):688-693. PubMed ID: 10764713
[TBL] [Abstract][Full Text] [Related]
3. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.
Beglinger C; Degen L; Matzinger D; D'Amato M; Drewe J
Am J Physiol Regul Integr Comp Physiol; 2001 Apr; 280(4):R1149-54. PubMed ID: 11247838
[TBL] [Abstract][Full Text] [Related]
4. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Lieverse RJ; Jansen JB; Masclee AA; Rovati LC; Lamers CB
Gut; 1994 Apr; 35(4):501-5. PubMed ID: 8174988
[TBL] [Abstract][Full Text] [Related]
5. Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans.
Gutzwiller JP; Drewe J; Ketterer S; Hildebrand P; Krautheim A; Beglinger C
Am J Physiol Regul Integr Comp Physiol; 2000 Jul; 279(1):R189-95. PubMed ID: 10896881
[TBL] [Abstract][Full Text] [Related]
6. Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans.
Drewe J; Gadient A; Rovati LC; Beglinger C
Gastroenterology; 1992 May; 102(5):1654-9. PubMed ID: 1568575
[TBL] [Abstract][Full Text] [Related]
7. Effect of cholecystokinin-A receptor blockade on lipid-induced gastric relaxation in humans.
Mesquita MA; Thompson DG; Troncon LE; D'Amato M; Rovati LC; Barlow J
Am J Physiol; 1997 Jul; 273(1 Pt 1):G118-23. PubMed ID: 9252517
[TBL] [Abstract][Full Text] [Related]
8. Effects of a specific CCK-A antagonist, Loxiglumide, on postprandial mood and sleepiness.
Wells AS; Read NW; Fried M; Borovicka J; D'Amato M
J Psychopharmacol; 1997; 11(3):241-6. PubMed ID: 9305416
[TBL] [Abstract][Full Text] [Related]
9. Bombesin reduces food intake after a preload in man by a cholecystokinin-independent mechanism.
Lieverse RJ; Jansen JB; Masclee AA; Lamers CB
Clin Sci (Lond); 1993 Sep; 85(3):277-80. PubMed ID: 8403798
[TBL] [Abstract][Full Text] [Related]
10. Effect of medium- and long-chain triglycerides on lower esophageal sphincter pressure: role of CCK.
Ledeboer M; Masclee AA; Biemond I; Lamers CB
Am J Physiol; 1998 Jun; 274(6):G1160-5. PubMed ID: 9696717
[TBL] [Abstract][Full Text] [Related]
11. Elevation of feed intake in parasite-infected lambs by central administration of a cholecystokinin receptor antagonist.
Dynes RA; Poppi DP; Barrell GK; Sykes AR
Br J Nutr; 1998 Jan; 79(1):47-54. PubMed ID: 9505802
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid.
Feinle C; D'Amato M; Read NW
Gastroenterology; 1996 May; 110(5):1379-85. PubMed ID: 8613041
[TBL] [Abstract][Full Text] [Related]
13. Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women.
Lieverse RJ; Masclee AA; Jansen JB; Rovati LC; Lamers CB
Biol Psychiatry; 1995 Mar; 37(5):331-5. PubMed ID: 7748985
[TBL] [Abstract][Full Text] [Related]
14. Physiological role of cholecystokinin on postprandial insulin secretion and gastric meal emptying in man. Studies with the cholecystokinin receptor antagonist loxiglumide.
Fried M; Schwizer W; Beglinger C; Keller U; Jansen JB; Lamers CB
Diabetologia; 1991 Oct; 34(10):721-6. PubMed ID: 1959704
[TBL] [Abstract][Full Text] [Related]
15. Effect of cholecystokinin1 receptor antagonist loxiglumide (CR1505) on basal pancreatic exocrine secretion in conscious rats.
Ishizaki K; Kinbara S; Kawamura M; Kimura K; Shiratori K; Takeuchi T
Pancreas; 2003 Jan; 26(1):87-91. PubMed ID: 12499923
[TBL] [Abstract][Full Text] [Related]
16. The effects of loxiglumide on food intake in normal weight volunteers.
French SJ; Bergin A; Sepple CP; Read NW; Rovati L
Int J Obes Relat Metab Disord; 1994 Nov; 18(11):738-41. PubMed ID: 7866473
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
Konturek JW
J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215
[TBL] [Abstract][Full Text] [Related]
18. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans.
Zerbib F; Bruley Des Varannes S; Scarpignato C; Leray V; D'Amato M; Rozé C; Galmiche JP
Am J Physiol; 1998 Dec; 275(6):G1266-73. PubMed ID: 9843762
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of the M1-receptor antagonist telenzepine and the CCK-receptor antagonist loxiglumide on the pancreatic secretory response to intraduodenal tryptophan in dogs.
Teyssen S; Niebergall-Roth E; Rausch A; Beglinger C; Riepl RL; Chari S; Singer MV
Pancreas; 1996 Nov; 13(4):407-16. PubMed ID: 8899802
[TBL] [Abstract][Full Text] [Related]
20. Role of cholecystokinin in the intestinal phase of pancreatic circulation in dogs.
Nakajima M; Naruse S; Kitagawa M; Ishiguro H; Jin C; Ito O; Hayakawa T
Am J Physiol Gastrointest Liver Physiol; 2001 Apr; 280(4):G614-20. PubMed ID: 11254487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
